Similar to the concept of Silicon Valley, Biotech Valley is in the making.
In the United States, the healthcare remains one of the cheapest sectors after the stock market rally since later 2016. Merges and acquisitions will happen more often in this particular sector this year than other sectors. I particularly like Bio Tech companies for the following additional reasons.
First, there are many breakthroughs in the gene repair and editing technologies. Nearly twenty years after the completion of the Human Genome Project, many industrial applications have emerged.
Second, the U. S. administration, speaking the FDA, will consider to speed up approval process for new drugs and new medical practices. This will benefit Bio tech startups and some big companies who have conducted researches in the bio techs.